When was RiboBio founded?

RiboBio was founded in 2004 and raised its 1st funding round 18 years after it was founded.

Where is RiboBio located?

RiboBio is headquartered in Guangzhou, China.

How many employees does RiboBio have?

As of Jun 30, 2026, the latest employee count at RiboBio is 10.

Is RiboBio a funded company?

RiboBio is a funded company, having raised a total of $***** in its 1st and only funding round, a Series E round on Jul 29, 2022.

When was the latest funding round of RiboBio?

RiboBio's latest funding was a $***** Series E round on Jul 29, 2022, with participation from 2 investors.

Where does RiboBio rank among its competitors?

RiboBio ranks 48th amongst 415 active competitors, of which 39 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Constructive Bio, which secured an undisclosed amount in Mar, 2025.

Who are the top competitors of RiboBio?

RiboBio's top competitors include Sino Biological, Enzo and Devyser. Among them, Constructive Bio secured the most recent funding round in March, 2025.

RiboBio - 2026 Company Profile, Funding & Competitors

RiboBio is a series E company based in Guangzhou (China), founded in 2004. It operates as a Developer of oligonucleotides. RiboBio has raised $40M in funding from Panlin Capital. The company has 415 active competitors, including 39 funded and 68 that have exited. Its top competitors include companies like Sino Biological, Enzo and Devyser.

Company Details

RiboBio develops oligonucleotides. They are specialized in the development and supply of DNA, RNA, RNAi, miRNA, and lncRNA products. The company has a GMP approved oligonucleotide manufacturing facility and also offers process development services. Their R&D service portfolio includes RNAi/miRNA functional studies, high-content high-throughput RNAi and small molecule screens, and mRNA and miRNA microarray analysis, and others. The company has developed a proprietary solid-phase RNA oligonucleotide synthesis process.

Website: www.ribobio.com
Phone Number: +86 **********

Key Metrics

Founded Year

2004

Location

Guangzhou, China

Stage

Series E

Total Funding

$40M in 1 round

Latest Funding Round

Series E, Jul 29, 2022, $*****

Investors

Panlin Capital & 1 more

Ranked

48^th among 415 active competitors

Employee Count

10 as on Jun 30, 2026

Similar Companies

ArcherDX & 194 more

View RiboBio's full profile

RiboBio has raised a total funding of $40M over 1 round. Its latest funding round was a Series E round on Jul 29, 2022 for $*****. 2 investors participated in its latest round. RiboBio has 2 institutional investors.

Here is the list of recent funding rounds of RiboBio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 29, 2022	2265256	Series E	6165138	3763525	1644943	9895064

Access funding benchmarks and valuations. Sign up today!

View details of RiboBio's funding rounds and investors

RiboBio's employee count trend

RiboBio has 10 employees as of Jun 26. Here is RiboBio's employee count trend over the years:

Uncover RiboBio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RiboBio include Sino Biological, Enzo and Devyser. Here is the list of Top 10 competitors of RiboBio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sino Biological 2007, Beijing (China), Series A	Provider of reagents,and kits for clinical research	$29.4M	Qiming Venture Partners, CTS Capital & 1 others	67/100
2nd	Enzo 1976, Farmingdale (United States), Acquired	Life science products and services for research, drug discovery, and manufacturing	$7M	-	65/100
3rd	Devyser 2004, Stockholm (Sweden), Public	Provider of molecular diagnostic kits for cancer, hereditary diseases, and reproductive disorders	$15.5M	Swedbank Robur, Fjarde AP-fonden & 1 others	61/100
4th	Firefly BioWorks 2009, Cambridge (United States), Acquired	Develops platform to allow multiplexed assays on standard laboratory instrumentation	$3.77M	Breton Capital Ventures, PBM Capital & 3 others	59/100
5th	Miltenyi Biotec 1989, Bergisch Gladbach (Germany), Funding Raised	Develops tools and products for research and clinical application	-	HHS, Europa	58/100
6th	ArcherDX 2013, Boulder (United States), Acquired	Developer of molecular cancer diagnostic products	$153M	Perceptive Advisors, PBM Capital & 8 others	58/100
7th	Sebia 1967, Evry Courcouronnes (France), Acquired	Developer of electrophoresis-based in vitro diagnostics products	-	HarbourVest Partners, Astorg Partners & 4 others	56/100
8th	BioIVT 1981, Westbury (United States), Acquired	Provider of in vitro diagnostic products and assay services	-	WILsquare Capital, Thompson Street Capital Partners ... & 4 others	56/100
9th	Constructive Bio 2022, Saffron Walden (United Kingdom), Series A	Provider of a platform for genome and polymer synthesis	$75M	Ahren, OMX Ventures & 9 others	55/100
10th	GenScript 2002, Piscataway (United States), Public	Provider of reagents and instruments for life sciences research	$15M	Kleiner Perkins, Vermögensclub & 1 others	55/100
48th	RiboBio 2004, Guangzhou (China), Series E	Developer of oligonucleotides	$40M	Panlin Capital, SANY Group	37/100